Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States
mBio, Volume 2, No. 1, Article e00309-10, Year 2011
Notification
URL copied to clipboard!
Description
A seven-valent pneumococcal conjugate vaccine (PCV7) introduced in the United States in 2000 has been shown to reduce invasive pneumococcal disease (IPD) in both vaccinated children and adults through induction of herd immunity. We assessed the impact of infant immunization on pneumococcal pneumonia hospitalizations and mortality in all age groups using Health Care Utilization Project State Inpatient Databases (SID) for 1996 to 2006 from 10 states; SID contain 100% samples of ICD9-coded hospitalization data for the selected states. Compared to a 1996-1997 through 1998-1999 baseline, by the 2005-2006 season, both IPD and pneumococcal pneumonia hospitalizations and deaths had decreased substantially in all age groups, including a 47% (95% confidence interval [CI], 38 to 54%) reduction in nonbacteremic pneumococcal pneumonia (ICD9 code 481 with no codes indicating IPD) in infants<2 years old and a 54% reduction (CI, 53 to 56%) in adults≤65 years of age. A model developed to calculate the total burden of pneumococcal pneumonia prevented by infant PCV7 vaccination in the United States from 2000 to 2006 estimated a reduction of 788,838 (CI, 695,406 to 875,476) hospitalizations for pneumococcal pneumonia. Ninety percent of the reduction in model-attributed pneumococcal pneumonia hospitalizations occurred through herd immunity among adults 18 years old and older; similar proportions were found in pneumococcal disease mortality prevented by the vaccine. In the first seasons after PCV introduction, when there were substantial state differences in coverage among<5- year-olds, states with greater coverage had significantly fewer influenza-associated pneumonia hospitalizations among children, suggesting that PCV7 use also reduces influenza-attributable pneumonia hospitalizations. © 2011 Simonsen et al.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC3025524/bin/mBio00309-10-sf01.pdf
https://efashare.b-cdn.net/share/pmc/articles/PMC3025524/bin/mBio00309-10-sf02.pdf
https://efashare.b-cdn.net/share/pmc/articles/PMC3025524/bin/mBio00309-10-sf03.pdf
https://efashare.b-cdn.net/share/pmc/articles/PMC3025524/bin/mBio00309-10-sf04.pdf
Authors & Co-Authors
Simonsen, Lone
United States, Bethesda
Sage Analytica
United States, Washington, D.c.
Milken Institute School of Public Health
Taylor, Robert J.
United States, Bethesda
Sage Analytica
Haber, Michael J.
United States, Atlanta
Emory University
May, Larissa S.
United States, Bethesda
Sage Analytica
United States, Washington, D.c.
The George Washington University
Klugman, K. P.
United States, Atlanta
Emory University
Statistics
Citations: 241
Authors: 5
Affiliations: 4
Identifiers
Doi:
10.1128/mBio.00309-10
ISSN:
21507511
Research Areas
Health System And Policy
Maternal And Child Health